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Abstract
Background: Previous evidence implicates polymorphisms of GSTM1 and GSTT1, candidates of
phase II enzymes, as risk factors for various cancers. A number of studies have conducted on the
association of GSTM1 and GSTT1 polymorphism with susceptibility to nasopharyngeal carcinoma
(NPC). However, inconsistent and inconclusive results have been obtained. In the present study,
we aimed to assess the possible associations of NPC risk with GSTM1 and GSTM1 null genotype,
respectively.
Methods: The associated literature was acquired through deliberate searching and selected based
on the established inclusion criteria for publications, then the extracted data were further analyzed
using systematic meta-analyses.
Results: A total of 85 articles were identified, of which eight case-control studies concerning NPC
were selected. The results showed that the overall OR was 1.42 (95%CI = 1.21–1.66) for GSTM1
polymorphism. While for GSTT1 polymorphism, the overall OR was 1.12 (95% CI = 0.93–1.34).
Conclusion: The data were proven stable via sensitivity analyses. The results suggest GSTM1
deletion as a risk factor for NPC and failed to suggest a marked correlation of GSTT1
polymorphisms with NPC risk.
Backgrounds
Nasopharyngeal cancer (NPC), a fast-growing tumour,
characterized by a high frequency of nodal and distant
metastasis at diagnosis, is rare in many areas of the world
but common in Southeast Asia [1]. Evidence suggests that
Epstein-Barr virus (EBV) infection is a major risk factor
contributing to its tumorigenesis [2]. Besides, cigarette
smoking and alcohol consumption are probably impor-
tant etiological factors increasing the risk of developing
NPC [3]. Moreover, environmental chemical pollutions,
widely spread carcinogens, are difficult to be degraded in
the environment and thus may have a long-term effect on
human health. Despite many individuals exposed to EBV
infection, environmental risk factors and/or with exten-
sive tobacco and alcohol consumption, NPC develops
only in a small group of exposed people, which suggests
that genetic host factors might contribute to the carcino-
genic mechanisms. Recent evidence indicates that carcin-
ogen-metabolizing genes and DNA-repair genes may play
critical roles in determining individual susceptibility to
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cancers. Polymorphisms in these genes encoding the
enzymes, possibly by altering their expression and func-
tion, may increase or decrease carcinogen activation/
detoxication and modulate DNA repair.
Xenobiotics can be detoxified by phase II enzymes, such
as GSTM1 and GSTT1 which have been suggested to be
involved in detoxification of polycyclic aromatic hydro-
carbons (PAHs) and benzo(a)pyrene [4]. Evidence sug-
gests that genetic polymorphisms of these genes might
increase individual susceptibility to NPC. Therefore, a
number of published studies have focused on GSTM1 and
GSTT1 genetic variation with respect to NPC and have
yielded conflicting results. Whether GSTM1 or GSTT1 pol-
ymorphism is a risk factor for NPC remains largely uncer-
tain.
Since a single study may have been underpowered to clar-
ify the associations of GSTM1 or GSTT1 polymorphisms
with NPC susceptibility, in the present study we aimed to
perform evidence-based quantitative meta-analyses that
might increase statistical power to address this contro-
versy.
Methods
Literature search strategy for identification of the studies
We carried out a search in the Medline, EMBASE and Chi-
nese National Knowledge Infrastructure (CNKI) without a
language limitation, covering all papers published up to
Sep 2008, with a combination of the following keywords:
GSTM1, GSTT1, nasopharynx or nasopharyngeal, head and
neck, cancer, carcinoma, tumour or neoplasm.
We evaluated potentially associated publications by
checking their titles and abstracts and then procured the
most relevant publications for a closer examination.
Moreover, the reference lists of the selected papers were
also screened for other potential articles that possibly
have been missed in the initial search. The following cri-
teria were used for the literature selection of the meta-
analysis:
1. Articles clearly describing studies in the association of
NPC with GSTM1 or GSTT1 polymorphisms;
2. Case–control studies;
3. The NPC diagnoses and the sources of cases and con-
trols should be stated;
4. The size of the sample, odds ratios (ORs) and their 95%
confidence intervals (CIs) or the information that can
help infer the results should also be offered;
5. Those publications that presented data allowing such
outcomes to be derived were also selected.
Accordingly, the following exclusion criteria were also
used:
1. Design and the definition of the experiments were obvi-
ously different from those of the selected papers;
2. The source of cases and controls and other essential
information was not offered;
3. Reviews and repeated literature.
After searching, we reviewed all papers in accordance with
the criteria defined above for further analysis. In addition,
Hardy-Weinberg equilibrium test [5] was conducted to
evaluate the genetic equilibrium for each study.
Data extraction
Data were extracted and entered into a database. The
extraction was performed by two reviewers independ-
ently. For conflicting evaluations, an agreement was
reached following a discussion.
Statistical analysis
The odds ratio (OR) of GSTM1 or GSTT1 polymorphisms
and NPC risk was estimated for each study. For detection
of any possible sample size biases, the OR and its 95%
confidence interval (CI) to each study was plotted against
the number of participants respectively. A Chi-square
based Q statistic test was performed to assess heterogene-
ity. If the result of the heterogeneity test was P > 0.05, ORs
were pooled according to the fixed-effect model (Mantel-
Haenszel), Otherwise, the random-effect model (DerSi-
monian and laird) was used. The significance of the
pooled ORs was determined by Z-test. The Hardy-Wein-
berg equilibrium was assessed via Fisher's exact test.
Publication bias was assessed by fail-safe number for P =
0.05 (Nfs0.05) [6]. Statistical analysis was undertaken
using the program Review Manager 4.2 and SAS 8.1 soft-
ware.
Results
Literature search and meta-analysis databases
A total of 85 studies regarding GSTM1 or GSTT1 were
identified (Fig. 1). After a careful review, irrelevant 71
papers were excluded. Then, the remaining 14 papers were
examined according to our inclusion criteria and finally 4
concerning GSTM1 [7-10], and 4 concerning both of
GSTM1 and GSTT1 [11-14] were selected. Of the included
8 studies, one was written in French [13], three in Chinese
[8,9,12] and the remaining four studies [7,10,11,14] were
written in English. The controls of the included studies are
in agreement with Hardy-Weinberg equilibrium. We
established a database according to the extracted informa-
tion from each article. The information was listed in Tab.
1. According to the lists, the first author and the numberJournal of Experimental & Clinical Cancer Research 2009, 28:46 http://www.jeccr.com/content/28/1/46
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of cases and controls for each study as well as other neces-
sary information were presented.
Test of heterogeneity
Fig. 2 shows the association between the GSTM1 deletion
and NPC risk. We analyzed the heterogeneity for all 8
studies and the test value of Chi-square was 6.73 with 7
degree of freedom (d.f.) and P > 0.05 in a fixed-effect
model. For the association between the GSTT1 null geno-
type and NPC risk, the Chi-square value for the heteroge-
neity of all 4 studies was 7.16 with 3 d.f. and P > 0.05 in a
fixed-effect model (Fig. 3).
Additionally, I-square value is another index for the heter-
ogeneity test [15], with value less than 25% indicating
low, 25% to 50% indicating moderate, and greater than
50% indicating high heterogeneity. In Fig. 2, the I-square
value was 0%, suggesting an absence of heterogeneity.
Thus, a fixed-effect model was used. However, in Fig. 3,
the I-square value was 58.1%, suggesting a possible pres-
ence of heterogeneity. Accordingly, both fixed-effect
model (Fig. 3) and random-effect model (Fig. 4) were uti-
lized for evaluation of GSTT1.
Quantitative data synthesis
For GSTM1 polymorphism, the data available for our
meta-analysis were obtained from 8 case-control studies
of 1112 cases and 1601 controls, of which 649 cases and
798 controls had the null genotypes (the exposure group)
and 463 cases and 803 controls had the GSTM1 present
genotype. The overall OR was 1.42 (95% CI = 1.21–1.66)
and the test for overall effect Z value was 4.39 (P < 0.05).
The results indicate that GSTM1 null genotype might have
an association with increased risks of NPC.
For GSTT1 polymorphism, the data available for our
meta-analysis were obtained from 4 case-control studies
of 790 cases and 1156 controls, of which 385 cases and
518 controls had the null genotypes (the exposure group)
and 405 cases and 638 controls had the present genotype
of the GSTT1 gene. As shown in Fig. 3, the overall OR for
the null genotype versus present genotypes was 1.12 (95%
CI = 0.93–1.34) and the test for overall effect Z value was
Table 1: Case-control studies on GSTM1/GSTT1 polymorphisms and NPC risk
First Author Publication Year Cases Controls Histology Ethnicity genotype Ref. number
Nazar-Stewart V 1999 83 142 11 Epithelial, Nos; 24 
Undifferentiated; 48 
Squamous
57 Caucasian; 7 African-
American; 17 Asian; 2 Native 
American
GSTM1 [7]
Da SJ 2002 80 80 72 Squamous, 8 
Adenocarcinoma
80 Asian (China) GSTM1 [8]
Cheng YJ 2003 314 337 Not Determined 314 Asian (China) GSTM1;
GSTT1
[11]
Deng ZL 2004 91 135 91 Squamous 91 Asian (China) GSTM1;
GSTT1
[12]
Liao ZL 2005 80 72 Not Determined 80 Asian (China) GSTM1 [9]
Tiwawech D 2005 78 145 Not Determined 78 Asian (Thailand) GSTM1 [10]
Bendjemana K 2006 45 100 Not Determined 45 Caucasian (France) GSTM1;
GSTT1
[13]
Guo X 2008 341 590 Not Determined 341 Asian (China) GSTM1;
GSTT1
[14]
The flow diagram of included/excluded studies Figure 1
The flow diagram of included/excluded studies.Journal of Experimental & Clinical Cancer Research 2009, 28:46 http://www.jeccr.com/content/28/1/46
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1.16 (P > 0.05) in a fixed-effect model. Moreover, the
overall OR was 1.16 (95% CI = 0.83–1.61) and the Z value
was 0.88 (P > 0.05) in a random-effect model (Fig. 4).
Both the two models suggest that GSTT1 polymorphism is
unlikely to associate with increased susceptibilities to
NPC.
Considering that the study [13] concerning Caucasians in
which the data might be different from the remaining
three studies regarding Asians, we excluded it and further
conducted a meta-analysis. As shown in Fig. 5, the overall
OR was 1.22 (95% CI = 0.85–1.76) and the test for overall
effect Z value was 1.09 (P > 0.05) in a random-effect
model. Likewise, the data failed to suggest a significant
association of GSTT1 deletion with NPC risk. Interest-
ingly, the three remaining studies were conducted in
China, suggesting that GSTT1 null genotype might not be
the factor increasing NPC risk in Chinese population.
Sensitivity analysis
In order to compare the difference and evaluate the sensi-
tivity of the meta-analyses, we also reported the results of
the random-effect model for GSTM1 as follows: the com-
bined OR and 95% CI were 1.42 (95% CI = 1.21–1.66),
similar to the results of the fixed-effect models. For
GSTT1, the results of the fixed-effect model and random
effect model were statistically similar, as stated in the
above section.
Additionally, we also conducted one-way sensitivity anal-
ysis [16] to evaluate the stability of the meta-analysis. For
GSTM1, the I-square value ranged from 0% to 10.4%
Meta-analysis with a fixed-effect model for the association of NPC risk with GSTM1 polymorphism (null genotype versus  present genotype) Figure 2
Meta-analysis with a fixed-effect model for the association of NPC risk with GSTM1 polymorphism (null geno-
type versus present genotype).
Meta-analysis with a fixed-effect model for the association of NPC risk with GSTT1 polymorphism (null genotype versus  present genotype) Figure 3
Meta-analysis with a fixed-effect model for the association of NPC risk with GSTT1 polymorphism (null geno-
type versus present genotype).Journal of Experimental & Clinical Cancer Research 2009, 28:46 http://www.jeccr.com/content/28/1/46
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when any single study was omitted, with the statistical sig-
nificance of the overall effect size unchanged. Neverthe-
less, for GSTT1, the I-square value varies between 64.4%
and 72% when any single study of Bendjemana [13],
Cheng [11] and Guo [14] was omitted, suggesting a possi-
ble presence of heterogeneity. Notably, when the study of
Deng [12] was excluded, the I-square equaled to 0%, indi-
cating that this study [12] may contribute to the possible
heterogeneity. However, the statistical significance of the
overall effect size was not altered whether the study [12]
was excluded or not. Hence, we could conclude that the
results of the studies concerning both GSTM1 and GSTT1
are stable and credible.
Bias diagnostics
Funnel plots were usually created to assess the possible
publication biases. In the meta-analyses, for GSTT1 and
GSTM1 polymorphisms, the funnel plots were not created
because it is useless when the number of the included
studies is limited. Nevertheless, fail-safe number, for the
evaluation of the reliability of meta-analysis, is defined as
the number of negative results that could reverse the sig-
nificant finding. The Nfs0.05 for GSTM1 polymorphism
was 66, suggesting that the publication biases might not
have a remarkable influence on the results of the meta-
analyses. Notably, for GSTT1 polymorphism, it is useless
to utilize fail-safe number for evaluation of publication
bias when the number of the included studies is only four.
Discussion
Previous evidence suggests that GSTM1 and GSTT1 poly-
morphisms may have a close association with increased
susceptibility to various carcinomas. In the present study,
the results of meta-analyses suggest that genetic deletion
of GSTM1 may contribute to increased susceptibility to
NPC whereas GSTT1 polymorphism may not.
Null mutations of GSTM1, one of the most important
phase II enzymes, are known to abolish enzyme activities
and therefore have been linked with increasing incidence
Meta-analysis with a random-effect model for the association between NPC risk and the GSTT1 polymorphism (null genotype  versus present genotype) Figure 4
Meta-analysis with a random-effect model for the association between NPC risk and the GSTT1 polymor-
phism (null genotype versus present genotype).
Meta-analysis with a random-effect model for the association between NPC risk and the GSTT1 polymorphism (null genotype  versus present genotype, with the reference 13 exclusion) Figure 5
Meta-analysis with a random-effect model for the association between NPC risk and the GSTT1 polymor-
phism (null genotype versus present genotype, with the reference 13 exclusion).Journal of Experimental & Clinical Cancer Research 2009, 28:46 http://www.jeccr.com/content/28/1/46
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of certain cancers, most likely due to increased susceptibil-
ities to environmental toxins and carcinogens. Previous
meta-analyses indicate that GSTM1 deficiency might have
a significant association with increased risks of breast can-
cer [17] and lung cancer in Chinese people [18]. Our pre-
vious meta-analyses concerning oral cancer suggest that
GSTM1 null genotype increases the oral cancer risk in
Asians but not Caucasians [19]. However, a number of
meta-analyses suggest no marked associations of GSTM1
null mutations with hepatocellular carcinoma [20], brain
tumors [21], gastric cancer [22], esophageal cancer [23]
and prostate cancer [24]. In this study, the results sup-
ported the notion that GSTM1 deficiency might increase
susceptibility to NPC.
Similarly, null genotype of GSTT1 has been suggested to
associate with risks of a number of cancers. Previous meta-
analyses suggest marked associations of GSTT1 deletion
with lung cancer [25], gastric cancer in Caucasians [26],
brain cancers [21], colorectal cancer [27], leukaemia [28]
and head and neck cancers that combined oral and pha-
ryngeal as well as laryngeal cancers [29]. In the present
meta-analysis, GSTT1 deficiency is unlikely to act as a risk
factor for NPC, in line with previous meta-analyses con-
cerning esophageal cancer [23], prostate cancer [24] and
breast cancer [30], respectively. Notably, for GSTT1, the
results should be interpreted with caution because of the
limited number of the included studies. Moreover, for
evaluation of the possible heterogeneity between the stud-
ies, we reported that the chi-square value was 7.16 and its
P value was 0.07 with an I-square 58.1%, suggesting that
a random-effect model should be used to address this
issue. Thus, a random-effect model was used (Fig. 4). The
data indicated the similarity between the two models,
confirming the stability of the results.
In this meta-analysis, we did not perform subgroup anal-
yses. First, for GSTM1 polymorphisms, the data showed
an absence of heterogeneity between the included studies.
In addition, the extracted data showed that most studies
were conducted on Asians. Of the eight studies, only a
French study concerned Caucasian while another Ameri-
can study concerned a combined population with several
ethnicities. Hence, a subgroup analysis regarding ethnic
stratification had not been performed. Second, for GSTT1
deletion, we excluded the French study that might be dif-
ferent from the other three studies. As a consequence, the
data failed to show a significant association of GSTT1 null
genotype with NPC risk in Asians (Fig. 5) or in the com-
bined population (Fig. 3). Third, we tried to extract any
data that concerned the possible relationship between
smoking and alcohol addiction as well as EBV infection.
Nevertheless, the primary studies did not show enough
relevant information. For the same reason, the combined
effects of both GSTM1 and GSTT1 deletion on NPC were
not assessed. However, in the present study, we success-
fully extracted the necessary data from the available pub-
lished papers for determination of the possible
associations between these genes and NPC risk.
The results of the present meta-analysis indicated a possi-
ble role of GSTM1 deletion in the tumorigenesis and pro-
gression of NPC. Nevertheless, the data failed to show a
significant association of GSTT1 null genotype with
increased susceptibility to NPC. This discrepancy might be
due to some reasons. For GSTT1, a gene that is highly con-
served during evolution, major ethnic differences exist in
frequency distribution. In East Asia, highest percentages of
individuals with the GSTT1 null genotype were reported
[31]. Interestingly, this incidence of NPC is high in East
Asia but is low in other regions worldwide. It seems that
GSTT1 deletion might have an association with increased
NPC risk. Nevertheless, conversely, it indicates that
although many people in East Asia carry GSTT1 null gen-
otype and, however, only a small group of people develop
NPC, implying that GSTT1 deletion might not be a key
event increasing susceptibility to NPC. For GSTM1, a GST
isoenzyme, has been reported to detoxify the bioreactive
diol-exoxides of PAHs which is important in environmen-
tal and occupational carcinogenesis [31]. Therefore, dele-
tion of GSTM1 might contribute to the tumorigenesis and
progression of NPC. In a more recent study [32], GSTM1
but not GSTT1 null genotype was indicated to associate
with head and neck cancer risk, in agreement with our
study. Additionally, as the number of the included studies
concerning GSTT1 was only four and their sample sizes
are small, it is likely that the discrepancy may be due to
chance because studies with small sample size may have
insufficient statistical power to detect a slight effect or may
have yielded a fluctuated risk estimate. Therefore, a
number of further studies with large sample sizes are
needed to address this issue.
Several limitations might be included in this study. Since
most of the included studies have conducted on Asians
and a few on Caucasians, the results must be interpreted
with caution. Further studies concerning populations in
other areas such as African and American are required to
diminish the ethnic variation-produced biases. Addition-
ally, a possible publication bias might have been intro-
duced as only published studies written in English and
Chinese as well as French that could be searched from
Medline database were included. Notably, we did not use
the funnel plots and Egger's linear regression test [33] for
assessment of any possible publication biases because of
the limited number of the included studies. Moreover,
many factors may affect the results the funnel plots, lead-
ing to a misunderstanding of the publication biases
[34,35]. However, the fail-safe numbers failed to indicate
evident publication biases. In this study, the sample sizesJournal of Experimental & Clinical Cancer Research 2009, 28:46 http://www.jeccr.com/content/28/1/46
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of several studies in the meta-analyses are rather small,
and, the pooled analyses were based upon a thousand
cases and a thousand controls, which are under power to
give a confirmed conclusion. Only two studies include
three hundred cases and rest studies included less than
one hundred cases. Authors need more cautions about
their results. Furthermore, the controls of several studies
were hospital-based normal individuals or patients with
other diseases. In addition, whether the NPC and control
groups were from the same socio-economic status or the
same geographic area have not been clearly stated in some
of the original papers. Hence, any selection biases might
exist. Therefore, a number of further investigations regard-
ing GSTM1 and GSTT1 polymorphisms and NPC risk are
required.
In conclusion, the data of the present meta-analyses indi-
cate GSTM1 polymorphism as a risk factor for NPC and
failed to show a significant association of GSTT1 poly-
morphism with NPC risk.
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